Ractigen Advances Phase II Trial of RAG-17 for SOD1-ALS
Nantong, China, August 7, 2026 Ractigen Therapeutics has announced a significant milestone in the development of its investigational RNA...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Nantong, China, August 7, 2026 Ractigen Therapeutics has announced a significant milestone in the development of its investigational RNA...
Nutley, New Jersey, USA, August 5, 2026 Reckitt has received U.S. Food and Drug Administration (FDA) approval for Mucinex®...
Galway, Ireland, August 6, 2026 Medtronic has secured an expanded CE Mark indication for its Afferaâ„¢ Mapping and Ablation...
